For years, digital biomarkers have seemed like a promising way to transform drug clinical trials, yet their adoption journey has been uneven. We’ve watched as the excitement for Proteus’s ingestible sensors dissolved when the company filed for bankruptcy. We’ve seen major investments to build large and sophisticated digital health teams by biopharma companies (e.g., Biogen) […] The post Keys to harnessing the value of digital biomarkers in clinical trials appeared first on Recon Str...
